GlassScriptPhysician profile
Dawn Hansen
NPI 1669814489
$1,077.38
in general payments reported to CMS, 2019-2025
15 companies · $65.00 in 2025
The $65.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $415 · 2023: $78.84 · 2024: $197 · 2025: $65.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.63 | 2021-2023 | |
| Therapeuticsmd, INC. | $129.30 | 2021-2022 | |
| Evofem Biosciences, INC. | $120.64 | 2021-2022 | |
| Biogen, INC. | $87.51 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $82.12 | 2024 | Veozah |
| Boston Scientific Corporation | $76.35 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $49.46 | 2022-2023 | |
| Organon LLC | $48.30 | 2022-2024 | |
| Hologic Sales and Service, LLC | $30.88 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.45 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $22.42 | 2024 | Myfembree |
| Daiichi Sankyo INC. | $19.48 | 2024 | Injectafer |
| Urovant Sciences INC | $19.43 | 2022 | |
| Becton, Dickinson and Company | $17.68 | 2022 | |
| Dexcom, INC. | $15.73 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.